+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
P

Actively Recruiting

Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.

Age: 18Years +All GendersPhase 3
246 locations
G

Actively Recruiting

Non-small cell lung cancer NSCLC is a disease where cancer cells grow uncontrollably in lung tissues. This trial evaluates whether the investigational drug telisotuzumab vedotin works better than docetaxel and assesses its safety in adults with previously treated NSCLC that overexpresses c-Met. The study is a Phase 3 randomized trial involving about 768 participants worldwide to compare disease activity and side effects of these treatments. Participants will be randomly assigned to receive either telisotuzumab vedotin every two weeks or docetaxel every three weeks, both given as intravenous infusions. Treatment continues until specific discontinuation criteria are met. Those who benefit may have the option to continue treatment through an extension or rollover study. The study aims to compare how these two treatments affect disease progression and survival. During the study, participants will have regular hospital or clinic visits for medical assessments, blood tests, side effect monitoring, and questionnaires. Researchers will measure progression-free survival and overall survival up to about 39 months, along with response rates and quality of life indicators. The study includes detailed safety monitoring and may involve a higher treatment burden than standard care.

Age: 18Years +All GendersPhase 3
317 locations
C

Actively Recruiting

Researchers are evaluating treatments for non-small cell lung cancer NSCLC in adults with a specific KRAS G12D gene mutation. NSCLC is a common lung cancer type, and when it worsens after initial chemotherapy and immune therapy, options are limited. This study aims to compare a new drug, setidegrasib, with the standard drug docetaxel to see which better controls cancer progression and survival. Participants receive either setidegrasib or docetaxel through intravenous infusion. Setidegrasib is given on days 1, 8, and 15 of each 21-day cycle, while docetaxel is given on day 1 of each cycle. Treatment continues until cancer worsens, side effects prevent further use, or other medical decisions stop treatment. Some on docetaxel may switch to setidegrasib if their cancer progresses. Tumor scans are done every 6 weeks in the first year and every 9 weeks afterwards. During the study, participants have regular safety checks and monitoring of their health. Researchers assess how long cancer stays controlled without worsening and overall survival. They also measure symptoms, tumor response, drug processing in the body, and side effects. After progression, follow-up calls occur every 12 weeks to check on the participants condition. The study may last up to about four years depending on the outcome measures.

Age: 18Years +All GendersPhase 3
23 locations
P

Actively Recruiting

Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
329 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
L

Actively Recruiting

Researchers are examining the long-term safety of nivolumab monotherapy and its combinations with other cancer therapies across various tumor types. This phase 2 study focuses on patients who have previously participated in Bristol-Myers Squibb-sponsored trials involving nivolumab and other cancer treatments. The goal is to monitor safety outcomes over an extended period while patients continue or resume treatment. Participants receive specified doses of nivolumab alone or in combination with other drugs such as ipilimumab, cabozantinib, trametinib, relatlimab, capecitabine, bevacizumab, temozolomide, and others according to their assigned study group. The study includes multiple experimental arms with different drug combinations and dosing schedules, all delivered as drug treatments. Participants continue treatment based on eligibility from their parent studies, including those who are on treatment hold or eligible for rechallenge. Throughout the study, participants undergo regular safety assessments to monitor adverse events, serious adverse events, immune-mediated effects, and any events leading to treatment discontinuation. Monitoring begins from the first day of treatment and continues up to 135 days after treatment ends. Researchers also track incidences of death during this period. The total participation duration spans from enrollment through ongoing treatment and post-treatment safety follow-up, with data collected to evaluate long-term treatment safety.

Age: 18Years +All GendersPhase 2
410 locations
O

Actively Recruiting

This research observes patients with BRAF V600E mutation-positive unresectable advanced or recurrent solid tumors, excluding colorectal cancer, to monitor the safety and effectiveness of dabrafenib and trametinib. It is a prospective, multicenter, single-arm, non-interventional observational study that collects real-world data under current medical practices. The study is conducted using an electronic data capture system and aims to gather long-term information especially in pediatric patients. Participants receive dabrafenib and trametinib as prescribed according to the Japanese Package Insert without treatment assignment by the study. Adult patients are observed for one year after starting treatment, while pediatric patients are followed for up to eight years regardless of whether they continue treatment, to collect extensive safety and response data during the reexamination period. The study aims to include approximately 65 adults and about 20 pediatric patients. During the study, researchers collect data on adverse events related to skeletal and sexual maturation in pediatric patients, overall response rate in adults, progression-free survival, changes in height and weight, and other safety outcomes. Data collection occurs throughout the observation periods for both adult and pediatric patients. The study is sponsored by Novartis Pharmaceuticals and is designed to provide important long-term safety and effectiveness information on these medications used in routine care.

Age: 6Years - 99YearsAll Genders
70 locations
P

Actively Recruiting

Researchers are evaluating a treatment for adults with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction GEJ cancer. The study compares the effectiveness and safety of a combination including trastuzumab deruxtecan T-DXd plus a fluoropyrimidine and pembrolizumab versus the current standard chemotherapy plus trastuzumab and pembrolizumab. The study includes a main group with PD-L1 CPS score 1 or higher and an exploratory group with PD-L1 CPS less than 1, aiming to improve first-line therapy options. Participants will be randomly assigned to one of four treatment groups the main group receives either T-DXd with fluoropyrimidine plus pembrolizumab or trastuzumab with platinum-based chemotherapy plus pembrolizumab the exploratory group receives either T-DXd with fluoropyrimidine or trastuzumab with platinum-based chemotherapy. T-DXd and pembrolizumab are given intravenously every three weeks, while chemotherapy varies between 5-FU, capecitabine, cisplatin, or oxaliplatin combinations. The study evaluates these regimens over the course of treatment to assess their impact on cancer progression. During the study, participants will have tumor samples collected to confirm HER2 and PD-L1 status and undergo imaging scans to measure tumor lesions. Heart function and lung health will be monitored to ensure safety. Researchers will assess progression-free survival and overall survival up to 59 months after randomization. Participants are expected to attend regular visits for treatment administration and safety evaluations over the treatment period and follow-up assessments according to the study schedule.

Age: 18Years +All GendersPhase 3
250 locations
G

Actively Recruiting

Researchers are conducting a global, Phase 3, randomized, open-label study to evaluate the effectiveness and safety of firmonertinib compared to the investigators choice of osimertinib or afatinib as first-line treatments. The study focuses on adults with locally advanced or metastatic non-small-cell lung cancer NSCLC who have specific uncommon EGFR PACC mutations and have not received prior therapy for advanced disease. Participants will be randomly assigned in a 11 ratio to receive either 240 mg of firmonertinib daily or the investigators choice of 80 mg osimertinib or 40 mg afatinib daily. The treatments are oral tablets taken once a day. The study will continue until disease progression or death, with assessments lasting up to approximately 4 years. During the study, participants will undergo regular evaluations including tumor progression and response assessments by blinded independent central review. Researchers will monitor safety through adverse event reporting and laboratory tests over approximately 5 years. The main outcomes measured are progression-free survival and overall response rate, with additional assessments of overall survival, duration of response, and treatment tolerability. Participation may last up to about 5 years, including treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
141 locations

1-10 of 11

1